Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Cash Flow Conversion Efficiency
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares cash flow conversion efficiency. Based on the latest financial reports, Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) has a cash flow conversion efficiency ratio of -0.053x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-507.58K) by net assets ($9.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (2023–2026)
Cash flow conversion efficiency of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares from 2023 to 2026. This chart illustrates how Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HKPD live share price for real-time trading data and today's change.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Cash Flow Conversion Ratio Explained
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares ranked by their cash flow conversion efficiency. Also see Hong Kong Pharma Digital Technology Hold market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ashtead Technology Holdings PLC
LSE:AT
|
0.233x |
|
artec technologies AG
F:A6T
|
-0.014x |
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
-0.019x |
|
ARIP Public Company Limited
BK:ARIP
|
0.160x |
|
Trinex Minerals Ltd
AU:TX3
|
-0.213x |
|
Ulaslar Turizm Yatirimlari ve Dayanikli Tuketim Mallari Ticaret Pazarlama AS
IS:ULAS
|
0.018x |
|
Prime Dividend Corp
TO:PDV
|
0.094x |
|
Wa Kaolin Ltd
AU:WAK
|
-0.953x |
Annual Cash Flow Conversion Efficiency for Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (2023–2026)
The table below shows the annual cash flow conversion efficiency of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares from 2023 to 2026. Review HKPD FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $9.58 Million | $-751.60K | -0.078x | -168.75% |
| 2025-03-31 | $4.99 Million | $569.21K | 0.114x | +223.05% |
| 2024-03-31 | $4.25 Million | $-394.33K | -0.093x | -103.14% |
| 2023-03-31 | $585.24K | $1.73 Million | 2.951x | -- |
About Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides valu… Read more